Across this cluster, sodium-glucose cotransporter-2 (SGLT2) inhibitors emerge as a pleiotropic drug class whose benefits extend well beyond glucose lowering in Type 2 Diabetes Mellitus. Nationwide Korean case-based analyses and nested case-control designs, drawing on national health insurance data (7,219 acute pancreatitis cases, 2018–2020) and propensity-matched cohorts (20,866 pairs), show SGLT2 inhibitors carry no elevated acute pancreatitis risk relative to DPP-4 inhibitors. Complementing this safety signal, Mendelian randomization confirms a causal gout-protective effect (~20% lower incidence versus DPP-4 inhibitors), and electronic health record-based studies demonstrate a neuroprotective association—reduced dementia incidence—particularly notable in the understudied high-risk group of patients with comorbid psychiatric disorders. Together these findings position SGLT2 inhibitors as a therapeutic class with cardiometabolic, renal, and now neurologic and rheumatologic relevance, reinforcing their centrality within the broader Cardiovascular-Kidney-Metabolic Syndrome framework, where composite risk indices (e.g., CHG index) and causal forest machine learning identify inflammation and HbA1c as effect modifiers of disease progression.
A second thread concerns lifecycle-specific vulnerability and prevention. At the adolescent end, an international panel of experts (including African and Middle Eastern low- and middle-income country representatives) has issued consensus recommendations targeting obesity and Type 2 Diabetes Mellitus prevention, acknowledging that socioeconomic and metabolic risk factors—not merely infection-related triggers like COVID-19—remain the dominant, geographically variable drivers of pediatric metabolic disease. At the older-adult end, the "ageing adipose paradox" reframes metabolic risk assessment: adipose tissue dysfunction (inflammation, ectopic fat deposition, altered adipokine secretion) occurs independently of BMI, meaning normal-weight older adults can harbor significant metabolic risk invisible to standard weight-based screening. This insight is pushing targeted interventions that assess adipose tissue quality rather than mass alone.
A third convergent theme is neurodegeneration resilience and risk stratification. The DELCODE cohort (8 German DZNE sites) exemplifies research into cognitive reserve—education and lifestyle factors—as a modifiable buffer against Alzheimer's disease biomarker burden in preclinical stages, moderated by factors like psychological debt. This resilience paradigm parallels the SGLT2 inhibitor–dementia relationship, suggesting two convergent but distinct trend lines: behavioral/educational resilience-building and pharmacologic neuroprotection, both aimed at dementia risk reduction in vulnerable, high-risk populations (psychiatric comorbidity, low cognitive reserve).
Collectively, this cluster reflects a macro-trend toward repositioning metabolic disease management as a multisystem, life-course endeavor—linking pediatric prevention policy, adipose tissue biology in aging, and drug repurposing of glucose-lowering agents for renal, cardiovascular, neurologic, and even rheumatologic outcomes, all increasingly validated through large real-world datasets, causal inference methods (Mendelian randomization, propensity matching, causal forests), and multinational consensus-building.